Erbitux 5mg/ml solution for infusion
Last Updated on eMC 09-Jun-2017 View document | Merck Contact details
When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.
Updated on 09-Jun-2017 and displayed until Current
Reasons for adding or updating:
- Change to section 4 - how to report a side effect
Updated on 16-Feb-2015 and displayed until 09-Jun-2017
Reasons for adding or updating:
- Change to section 4 - how to report a side effect
- Change to section 1 - what the product is
- Change to section 3 - how to take/use
Updated on 18-Mar-2014 and displayed until 16-Feb-2015
Reasons for adding or updating:
- Change to section 1 - what the product is used for
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 4 - how to report a side effect
Updated on 20-Jun-2013 and displayed until 18-Mar-2014
Reasons for adding or updating:
- Change to section 4 - possible side effects
- Removal of one or more presentations from joint PIL
Updated on 08-Jun-2012 and displayed until 20-Jun-2013
Reasons for adding or updating:
- Updates to formatting
- Change to how the medicine works
- Change to date of revision
- Change to storage instructions
- Change to side-effects
- Change to drug interactions
Updated on 10-Apr-2012 and displayed until 08-Jun-2012
Reasons for adding or updating:
- New PIL for eMC ie a PIL for an existing product but one that is new to the eMC
Merck
Merck Serono Ltd, Bedfont Cross, Stanwell Road, Feltham, Middlesex, TW14 8NX, UK
+44 (0)208 818 7267
+44 (0)208 818 7200
+44 (0)208 818 7373
+44 (0)208 818 7274
Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?
Active ingredients
Legal categories
This site uses cookies. By continuing to browse the site you are agreeing to our policy on the use of cookies. Continue